INTRODUCTION
Human pathogens that initiate disease following infection of mucosal surfaces represent the single largest cause of morbidity and mortality among the world's populations (2) . Diarrheal and respiratory illnesses are among the most common debilitating infectious diseases afflicting people of all ages around the globe. Although extensive research has been conducted to determine the role of cell-mediated immunity and serum antibodies in protection against infectious agents, less is known about the role of mucosal immunity. One major limitation on the development of effective immunoprophylaxis against mucosal pathogens may be the inability to stimulate significant levels of mucosal antibody directed against specific virulence determinants of the pathogens that cause these diarrheal and respiratory diseases.
Parenterally administered vaccines are not effective for eliciting mucosal secretory immunoglobulin A (sIgA) responses and are generally ineffective against organisms that colonize mucosal surfaces and do not invade: hence the relative ineffectiveness of the parenteral cholera vaccine. Orally administered vaccines, especially live attenuated vaccines, have been shown to be effective in inducing specific sIgA responses (17, 34) , presumably because antigen is delivered to the T and B lymphocytes of the gut-associated lymphoid tissue (GALT). The primed B cells then migrate to the mesenteric lymph nodes and undergo differentiation. These B cells enter the thoracic duct and then the general circulation and subsequently seed all of the secretory tissues * Corresponding author.
of the body, including the lamina propria of the gut and respiratory tract. IgA is then produced by the mature plasma cells and is transported onto the mucosal surface, where it is available to interact with invading pathogens (17, 31) (Fig.  1 ). Oral immunization at the level of the gut mucosa can elicit production of secretory antibodies on all mucosal surfaces (17, 34) . This greatly enhances the potential of this technique for immunization against infectious diseases.
One recent innovation in this approach has been to use avirulent derivatives of Salmonella spp. as carriers for plasmids that code for virulence determinants of heterologous mucosal pathogens. This technique has been examined with a number of antigens and has been shown to be an effective means of stimulating significant levels of specific mucosal sIgA directed against the carrier strain and the heterologous antigen. This review will focus on the background and application of this approach to vaccine delivery.
IMMUNIZATION AGAINST ENTERIC DISEASES
Enteric diseases such as cholera, dysentery, Escherichia coli-related diarrheas, typhoid fever, and enterovirus infections are major causes of morbidity and mortality worldwide, especially in developing countries, where sanitation conditions are less than adequate. Several types of vaccines against these enteropathies have been developed and tested over the years, among them killed whole cells, subunits of toxins, and live attenuated bacteria and viruses administered parenterally or orally.
Although widely used, parenterally administered vaccines against these diseases have not proved satisfactory. Results based on well-controlled field trials and human volunteer studies (59, 114) of typhoid fever, in which the organisms disseminate systemically, parenterally administered vaccines result only in marginal protection and short-lived immunity. This failure to provide adequate protection is observed despite the development of high titers of circulating antibodies and may be mostly due to an inadequate stimulation of local immunity (53) . In addition, parenteral administration of large numbers of killed organisms frequently results in adverse reactions such as local discomfort, redness, swelling, fever, headache, myalgia, and general malaise (1, 21, 73, 145) . More severe systemic manifestations such as anaphylactic shock, acute renal disease, appendicitis, and erythema nodosum, although rare, have also been observed (13, 75, 80, 101) . Oral killed vaccines against typhoid fever do not generally produce side effects but have been shown to induce only low levels of circulating and secretory antibodies and insignificant levels of protection against challenge (59) . In contrast, when examined in a field trial in Bangladesh, the oral vaccine against cholera, which consists of killed whole cells and partially purified cholera toxin B subunit, was shown to provide moderate protection for up to 24 months (22, 23, 137, 138) . The protective efficacy of the B-subunit killed whole-cell vaccine was 62% in the first year and 57% in the second year in all age groups for vaccinees receiving three doses. However, by the third year, the protective efficacy had fallen to 17% in all age groups, primarily as a result of the inability to evoke protection in children below the age of 5 years.
Historically, one of the main obstacles to the use of live vaccines was the potential reversion of attenuated strains to virulence. However, in recent years the mechanisms by which a number of pathogens cause infections have been Phosphatase deciphered and manipulation at the molecular level and the application of modem DNA technology have made possible the construction of safe, genetically stable mutants. Mass production, distribution, and administration are easier and less costly for such live attenuated vaccines than for purified component vaccines. This is of great importance since enteric diseases are a leading health problem mainly in countries that cannot afford expensive vaccination programs.
Presently, the only live attenuated enteric bacterial vaccine available for human use is a galactose epimerase-less (galE) mutant of Salmonella typhi designated Ty2la. This mutant was developed by Germanier and Furer in 1975 (61) by using the mutagenic alkylating agent nitrosoguanidine to treat the wild-type strain S. typhi Ty2. This galE mutant also had a 25% reduction of galactokinase and galactose-1-phosphate uridylyltransferase. The mutant was found to be stable; reversion to the parental phenotype has not been demonstrated in vitro or in vivo (10, 11, 61, 62, 88) . In the wild-type strain, the galactose needed for the synthesis of smooth lipopolysaccharide (LPS) 0 antigen is derived from UDP-galactose, which is made by UDP-galactose epimerase from UDP-glucose (Fig. 2) . When grown in the absence of galactose, Ty2la has a rough LPS, because it has no source of UDP-galactose. When sufficient galactose is added to the medium, the bacteria have a normal LPS composition but lyse, presumably because of the accumulation of the intermediates galactose-1-phosphate and UDP-galactose to toxic levels. This property, coupled with the fact that Ty2la is also Vi antigen negative, is a factor in the safety of the vaccine strain in vivo (see below). The safety and efficacy of S. typhi Ty2la as a human vaccine have been tested in volunteer galE Galactose -p Galactose Gal-l-P c > UDPGal " '(-UDPGlu E > Glu-l-P .
-Glu-6-P Delivering soluble antigens with immunopotentiating substances has also been investigated. Muramyl dipeptide, an orally administered adjuvant, has been shown to elevate the salivary IgA responses in rats that received both it and S. mutans-derived glucosyl transferase (141) . A number of bacterial and viral antigens have been administered in conjunction with cholera toxin or the closely related heat-labile enterotoxin of E. coli or their B subunits. Cholera toxin and the heat-labile enterotoxin are potent mucosal adjuvants, and their B subunits bind with high specificity to GM, gangliosides on mucosal epithelial cells (26, 39, 48, 97) .
An approach that has been proposed more recently is the use of live attenuated organisms as vectors to deliver specific target antigens to the host (55, 151 (103) , rabbits (121) , fowl (7, 8) , and mice (4, 35, 45, 51, 60, 71, 82, 112, 127) . This is attributed to the fact that live salmonellae reach the Peyer's patches, where they present their array of antigens directly to the T and B lymphocytes of the GALT, therefore priming the mucosal immune system to produce antigen-specific immune responses. This has prompted many investigators to consider and test the use of live attenuated Salmonella strains as carriers of genes coding for virulence determinants from other pathogenic microorganisms.
ATTENUATION OF SALMONELLA STRAINS Attenuated Salmonella spp. with reduced virulence for their hosts were first described in 1951 (3, 4) , when auxotrophic Salmonella mutants with exogenous requirements for purines, p-aminobenzoic acid, and aspartate were observed to exhibit reduced virulence for mice. Since then, a number of attenuated strains of all Salmonella species have been described. Some of the more widely investigated are discussed below.
galE Mutants Germanier and Furer noted that S. typhimurium and S. typhigalE mutants obtained after nitrosoguanidine mutagenesis were avirulent but still immunogenic in mice and humans, respectively. Those authors were the first to propose the use of S. typhi galE Ty21a as a vaccine against typhoid fever in humans (60, 61) . S. typhi Ty2la is phenotypically rough when grown in the absence of galactose but can produce complete LPS and become invasive when exogenous galactose is added to the medium (110) . These mutants lyse in the presence of high concentrations of galactose, presumably because of the accumulation of toxic levels of phosphorylated galactose (Fig. 2) (57, 58) . It is not known exactly whether the avirulence of these galE mutants is due to galactose sensitivity, the inability to synthesize LPS, the fact that they are also unable to synthesize Vi antigen, or unidentified mutations in genes that confer important virulence properties. The importance of galactose sensitivity as a virulence determinant is uncertain. On the one had, S. typhimurium galE mutants that were rendered galactose resistant by a second mutation became virulent for mice. However, S. choleraesuis galE mutants still retain virulence for mice (111, 112) and galE via (Vi antigen-negative) mutants of S. typhi Ty2 (strain EX462) retain virulence for humans (72) . In the study reported by Hone et al. (72) , two of four human volunteers receiving one dose of 7 x 108 S. typhi EX462 developed typhoidlike disease with fever and bacteremia. These authors examined the virulence of EX462 only at high doses, so it is not possible to determine the extent of low-dose attenuation. It is clear that the combined galE and via mutations did not attenuate S. typhi Ty2 sufficiently to make it safe for use at high doses in humans.
With the cloning and characterization of the S. typhimunum galactose operon, S. typhimurium galE mutants carrying defined deletions of the galE gene have also been constructed. These mutants have been shown to be avirulent and immunogenic in mice (71) , in contrast to the results obtained with EX462 in humans.
aro and pur Mutants Mutants with a block in the aromatic pathway have been isolated by transposon mutagenesis (69) . By using transposon TnlO, which carries the gene that confers resistance to tetracycline, a transposon insertion into the aroA gene was generated and subsequently transduced into virulent S.
typhimurium. Nonreverting aroA strains, selected after penicillin enrichment in fusaric acid-containing media, were demonstrated to carry a deletion in the aroA gene caused by the imprecise excision of the transposon. The same technique has been used by these (69) and other (129, 130, 134) investigators to obtain other Salmonella aroA deletion mutants for use as parenterally administered antisalmonellosis vaccines in calves. The aroA gene codes for the synthesis of 3-enolpyruvylshikimate-5-phosphate synthetase, which catalyzes the conversion of phosphoenolpyruvate and shikimate 3-phosphate into 5-enolpyruvoylshikimate-3-phosphate in a pathway that eventually leads to the synthesis of chorismate, a common intermediate compound in the synthesis of aromatic amino acids, p-aminobenzoic acid (essential for folate synthesis), 2,3-dihydroxybenzoic acid (needed for production of enterochelin, an iron chelator), p-hydroxybenzoic acid (precursor of ubiquinone), and o-succinylbenzoic acid (precursor of vitamin K) (Fig. 3) (42, 45, 100) and of S.
typhi for humans (140) .
Nonreverting, purine-requiring S. typhi and S. typhimu- (35) (36) (37) . The Acya Acrp double-deletion mutation has also been shown to reduce the virulence of S. typhi Ty2 for humans (140) .
Plasmid-Cured Strains High-molecular-weight plasmids have been associated with virulence in several nontyphoid Salmonella strains: S. typhimurium (63, 65, 66, 68, 76, 116) , S. dublin (18, 93, 142) , S. enteritidis (105) , and S. gallinarum (8, 9) . It was observed that elimination of the plasmid from these strains resulted in reduced virulence and that in some cases, reintroduction of the plasmid restored complete virulence. For S. gallinarum, which causes a dysenterylike syndrome in fowl, the plasmid has been associated with the ability of the organisms to invade via the intestinal mucosal epithelium and to survive and grow in cells of the reticuloendothelial system (9) . However, the exact contribution of these plasmids to virulence is uncertain. It has been suggested that, given the reduced virulence traits of these plasmid-cured strains, they may be useful as live attenuated vaccines. Experiments to test this hypothesis have been conducted by several investigators, who have observed that immunization with plasmid-cured strains provides some level of protection against challenge with the virulent organism in chickens and mice (7, 52, 106) . Characterization of the plasmid genes and their relationships to other virulence determinants in Salmonella spp. is necessary before the plasmid-cured strains can be used as commercial vaccines.
Streptomycin-Dependent Mutants
Streptomycin-dependent Salmonella strains described by Reitman and Iverson (120, 121) and Mel et al. (98) were isolated after repeated cultivation of pathogenic S. typhi in the presence of streptomycin. The rationale used to obtain these strains is that the organisms can become dependent on the antibiotic without exposure to more severe mutagenic agents that might destroy important protective antigens in the bacterial cell. In host tissues in which streptomycin is not available, the bacteria should not be able to grow and proliferate.
Streptomycin-dependent strains were isolated for use as vaccines against typhoid fever and were tested in both animals (121) and humans (87) . It was observed that when mice were simultaneously injected with streptomycin and given the vaccine, the LD50 of the attenuated strain was only 10-fold lower than the LD50 of the parental strain. Reitman and Iverson noted that parenteral immunization of rabbits with the streptomycin-dependent strain induced humoral antibodies against the 0 antigen of the vaccine strain (121). Levine et al. (87) tested the efficacy of this vaccine in human volunteers and observed that multiple doses of freshly harvested organisms (1011 CFU) did not provoke adverse effects when administered concomitantly with 1 g of streptomycin and 2 g of sodium bicarbonate and that after challenge with the wild-type strain, immunization with streptomycin-dependent S. typhi afforded a moderate level of protection (66 to 78% efficacy). In contrast, the same vaccine regimen with lyophilized reconstituted bacteria did not confer on the vaccinees any protection against clinical typhoid fever. Although the reason for this discrepancy is not known, it is obvious that a vaccine strain that loses its immunogenicity upon lyophilization could not be a good candidate for mass vaccination.
Aspartate Semialdehyde Dehydrogenase Mutants Diaminopimelic acid is a unique and essential constituent of the rigid layer of the bacterial cell wall. This component is part of a tetrapeptide that cross-links the glycan strands to form peptidoglycan. The enzyme aspartate semialdehyde dehydrogenase catalyzes the conversion of aspartate-4-phosphate to aspartate semialdehyde in a pathway that leads to the synthesis of threonine, methionine, lysine, and diaminopimelic acid (28) . Salmonella strains with a mutation in the asd gene are unable to synthesize normal peptidoglycan and lyse rapidly in the absence of exogenous diaminopimelic acid. These strains are avirulent for mice by all routes of inoculation, but their survival time in the GALT is so limited that their immunogenicity is very reduced (33) .
phoP and ompR Mutants Studies on the mechanisms of intracellular survival by S.
typhimurium have led to the isolation of TnlO insertion mutants that are unable to survive within macrophages in vitro and are avirulent for mice in vivo. Molecular and genetic analyses of these mutants indicated that all strains exhibiting the avirulent phenotype had the transposon inserted into the phoP gene, which has been hypothesized to be a regulator for the gene that encodes a nonspecific acid phosphatase. These studies indicate that phoP may also regulate genes involved in the resistance to antimicrobial factors in the host (51) .
Transposon-generated mutations have also led to the isolation of strains lacking one or more outer membrane proteins. Mutations in the ompC or ompF genes did not affect virulence, whereas strains with mutations in ompR failed to kill mice after oral or intravenous inoculation. It has been proposed that ompR encodes a positive regulator for the expression of other outer membrane proteins, a tripeptide permease, and other uncharacterized proteins involved in the transport of nutrients and the exclusion of harmful substances from the bacterial cell (41) . The immunogenicity ofphoP and ompR strains has yet to be tested. Formal et al. (55) were the first to report the use of an avirulent Salmonella sp. as a carrier for a heterologous antigen. A high-molecular-weight, naturally occurring plasmid of Shigella sonnei that codes for a cell surface antigen termed form I was conjugally transferred into the human live vaccine S. typhi Ty2la. The recipient strain was shown to contain both the form I plasmid of Shigella sonnei and the F' lac(Ts)::Tn3 plasmid used to mobilize the form I plasmid. Moreover, the transconjugant expressed both the form I antigen and the normal somatic antigens of S. typhi. Animal studies demonstrated that mice immunized intraperitoneally or subcutaneously with the recombinant vaccine were protected against challenge with either S. typhi or Shigella sonnei and that rabbits inoculated intravenously developed high titers of agglutinating antibodies against both the vaccine strain and the foreign antigen. This vaccine has been subsequently tested in human volunteers (11, 144, 146) and has been shown to be safe, to stimulate a significant IgA intestinal response against Shigella sonnei LPS, and to afford good but variable protection against bacillary dysentery. The inability to make reproducibly efficacious vaccine lots limits further use of this candidate vaccine.
Clements and El-Morshidy (25) were the first to introduce a recombinant plasmid into an attenuated Salmonella strain for use as a vaccine carrier. They constructed a potential live oral vaccine for typhoid fever and the cholera-E. coli-related diarrheas by transforming S. typhi Ty2la with a recombinant plasmid carrying the gene for the production of the binding subunit of the heat-labile toxin (LT-B) from enterotoxigenic E. coli. The S. typhi Ty2la derivative, designated SE12, was shown to express LT-B that was recognized by antibody against native LT-B produced in E. coli. This recombinant strain caused no diarrhea or other adverse effects in guinea pigs after oral inoculation. When injected intraperitoneally into mice, SE12 induced the production of high levels of antitoxin antibodies that could be specifically boosted with a subsequent injection of the vaccine strain or purified LT-B. To further evaluate the efficacy of this system, Clements et al. (27) The ability of avirulent Salmonella strains to evoke a cellular as well as a humoral antibody response against a heterologous antigen was first demonstrated by immunizing mice intravenously with an S. typhimurium aroA strain carrying a recombinant plasmid coding for the production of the intracellular protein 3-galactosidase. It was observed that after primary immunization and one booster with the vaccine strain, there was a delayed-type hypersensitivity response, as measured by footpad swelling (15, 43) , to ,B-galactosidase.
Shigella flexneri serotype 2a is one of the major etiological agents of shigellosis in the United States. In an effort to develop a vaccine against shigellosis, Baron et al. (6) used bacteriophage Mu-induced transposition to clone the genes specifying the type and group antigens from Shigella flexneri 2a into a plasmid. The group antigen that specifies the 0 repeat unit backbone is encoded by a gene located near the his marker at min 44 on the Shigella chromosome; the type antigen locus (type 2), which controls the modification of the 0 repeat unit, is located at min 6. The genetic construct was obtained by using Shigella flexneri carrying an F' lac::Mu cts62 plasmid grown at the permissive temperature for transposition of Mu. One of the plasmid isolates that carried thepro and his regions of Shigella flerneri 2a was conjugally transferred into a spontaneous pro his mutant of S. typhi Ty2la. The resulting strain (WR4086) agglutinated with rabbit anti-Shigella flexneri 2a serum and with anti-S. typhi Ty2 serum. However, in serum adsorption studies, strain WR4086 failed to remove all the S. typhi Ty2la 0 antigens. When examined in a mouse protection test, this strain provided significant protection against intraperitoneal challenge with Shigella flexneri 2a but not with the wild-type strain S. typhi Ty2. The authors reasoned that this lack of protection was due to the predominance of Shigella 0 antigens on the bacterial surface; the vaccine strain did not express sufficient S. typhi Ty21a somatic antigens to induce protective anti-S. typhi antibody levels in the mice.
M protein, an antiphagocytic virulence factor from Streptococcus pyogenes, has been cloned and expressed in an S. typhimunum aroA attenuated strain. Mice orally immunized with this potential vaccine developed anti-M-specific (type 5) serum IgG, IgA, and IgM as well as specific salivary sIgA. Immune serum was observed to have significant opsonizing activity against virulent Streptococcus pyogenes, and vaccinated mice challenged intraperitoneally or intranasally were protected against challenge with Streptococcus pyogenes type 5 but not against Streptococcus pyogenes type 24 (119) . The M protein from Streptococcus equi, the causative agent of strangles in horses, has also been cloned into an S.
typhimuium Acya Acrp avirulent strain, but thus far no immunogenicity or animal studies have been reported (36 (29) . The plasmid carrying the gene was unstable in vitro, since 50% of the bacteria lost the plasmid after 35 generations of growth under nonselective conditions. In contrast, it was observed that the same plasmid exhibited good stability in vivo, since only 1% of the colonies recovered from spleens of immunized mice had lost the plasmid. Immunization studies with mice showed that the vaccine did not induce any protection against challenge with dengue virus, but, on the contrary, vaccinated animals reacted more severely to the challenge than unvaccinated controls did. It has been observed that different strains of mice show variable ranges of susceptibility to Salmonella infection, and, moreover, it has been suggested that infection with Salmonella strains may induce some degree of immunosuppression in the animals (68 (12) .
Rotaviruses cause most of the diarrheal illness in infants and young children in industrialized nations. This infection is limited to the gastrointestinal tract; therefore, the induction of specific mucosal antibodies plays a major role in preventing the infection. A surface glycoprotein (VP7), which is known to induce neutralizing antibodies, was cloned, and a DNA segment coding for about 86% of the protein was expressed as a fusion product with P-galactosidase in the attenuated S. typhimurium aroA SL3261. The plasmid used for this experiment carried the rop gene, which decreases the copy number of ColEl-related plasmids, since it was observed that overproduction of the fusion peptide was toxic VOL. 5, 1992 on December 28, 2017 by guest http://cmr.asm.org/ Downloaded from for the bacterial cells. After 40 generations in vitro, approximately 90% of the bacteria retained the plasmid without selective pressure. In contrast, only 30% of the bacteria recovered from mice tissues at day 35 (136) , who used the aroC gene as the site of integration for the heterologous gene and an S. typhimunum polA mutant as the recipient of the recombinant plasmid. Two heterologous antigens were integrated into the Salmonella chromosome by this system: the C fragment of tetanus toxin and the tpd gene from T. pallidum, which encodes a lipoprotein product. Both antigens were expressed, albeit at lower levels than when carried on a plasmid. Results of stability and immunization studies with these recombinant strains are not available.
In a more recent report (54), a chromosomal expression vector was devised by using a modified version of the minitransposon mini-TnlO carried on bacteriophage lambda. This vector possesses a transposase gene located outside of the transposable portion of the transposon, which in itself carries a kanamycin resistance gene and an ot-lacZ fragment under the control of a lacUV5 promoter. The gene coding for the sporozoite protein from P. yoelii (CS) was cloned into this vector fused to the lacZ transcription signals. This construct was transformed into E. coli, and positive clones were introduced into a restriction-deficient S. typhimurium. In the absence of the lac repressor, the transposase is expressed and the mini-TnlO, along with the CS gene, transposes into the chromosome. The last step in this system involves the transduction of the insertions into an attenuated Salmonella vaccine strain by using a P22 lysate. The heterologous protein was expressed by the recombinant strain as detected by immunoblots of whole-cell lysates with an There are several points to consider regarding the observed instability of the plasmid expressing the recombinant antigen when the strains are grown in the presence or absence of the stabilizing antibiotic. It should be noted that a number of the studies reported were performed with the genes coding for recombinant antigens on plasmids with a pMB1 origin of replication (147) . The relative instability of these plasmids has been widely noted by a number of investigators (29, 54, 107, 113, 123, 124 (5) have examined a number of factors related to these questions, including (i) the nature of the humoral response if two Salmonella strains that are serologically identical or serologically different are used, (ii) the temporal relationship of priming and boosting doses on the subsequent immunologic response to the carrier and the foreign antigen, and (iii) differences in serum IgG and mucosal IgA responses between immunologically experienced and immunologically naive animals.
In their findings, immunologic experience with homologous and heterologous Salmonella serotype strains potentiated the subsequent antibody response when the same strains were used as vaccine carriers of foreign antigens. This potentiation was positively correlated with the appearance of antibody directed against the LPS of the carrier strain. Both serum and mucosal antibody responses against the foreign antigen increased over time. Serum antibody responses in mice primed with either the homologous or the heterologous serotype strain were not statistically significantly different, whereas mice primed with the homologous serotype strain developed significantly better mucosal antibody responses against the foreign antigen. The findings of Bao and Clements (5) indicated that immunologic experience with a Salmonella strain as a vaccine against typhoid fever or as a carrier for one foreign antigen will not preclude its subsequent use as a carrier for antigens of other pathogens. Immunologic experience with one strain does not limit the immunologic response to a foreign antigen delivered by the same strain or a second, immunologically related strain.
CONCLUSIONS
The use of attenuated Salmonella strains as vaccine delivery vehicles for heterologous antigens has been extensively studied in a number of animal species and in humans. These mutants are able to establish a limited infection in the host, and during the natural course of this innocuous infection, the bacteria deliver a series of in vivo-synthesized antigens directly to the B and T lymphocytes present in the GALT. The primed B cells migrate to the mesenteric lymph nodes, where they undergo differentiation, enter the general circulation via the thoracic duct, and subsequently populate the gut and other mucosal tissues, where clonal expansion and terminal differentiation into plasma cells occur. It has been demonstrated that immunization with these bivalent vaccines is an effective and safe way to elicit the production of serum and mucosal antibodies against both the Salmonella carrier and the foreign antigen. However (89) .
Moreover, mutations that attenuate Salmonella strains normally pathogenic for mice do not necessarily attenuate to the same degree Salmonella strains that are pathogenic for humans (i.e., galE mutations in S. typhimurium) (72) .
(v) The mouse model using appropriately attenuated Salmonella mutants is a relevant model system for testing this mechanism of antigen delivery but is not without limitations.
It is important to determine the effectiveness of this system of vaccination in an animal model that will permit challenge studies. In general, the lack of relevant animal models has hindered the final assessment of all of the candidate Salmonella-based vaccines developed to date. In a number of studies, vaccination and challenge experiments have been performed via intraperitoneal or intravenous injection. Since this route of inoculation deviates from the natural route of infection used by mucosal pathogens, the conclusions concerning efficacy and protection deduced from these kinds of experiments may not apply to natural challenge by the virulent organisms. Furthermore, when the end point of the challenge experiments is death, as in the mouse protection assays, it is not possible to determine the individual contributions of mucosal, serum, and cell-mediated immune responses to animal survival.
(vi) Antigen expression can be stabilized by a variety of mechanisms including use of plasmids that complement metabolic defects on the host strain (38, 107) and integration of the heterologous gene into the host chromosome (16, 54, 70, 136) .
(vii) Immunologic experience with a Salmonella strain as a vaccine against typhoid fever or as a carrier for one foreign antigen will not preclude its subsequent use as a carrier for antigens of other pathogens. As demonstrated by Bao and Clements (5), immunologic experience with one strain does not limit the immunologic response to a foreign antigen delivered by the same strain or a second, immunologically related strain. 
